Skip to main navigation

Careers    |    Contact    |    News    |   

  • About Arbutus
    • Overview
    • Management
    • Our Board
    • Scientific Advisory Board
    • Careers
  • About HBV
    • HBV Background
    • HBV Science
    • The Baruch S. Blumberg Institute
  • >
  • R&D Portfolio
    • HBV Assets
      • AB-729 (GalNAc-RNAi)
      • AB-836 (Oral Capsid Inhibitor)
      • AB-101 (Oral PD-L1 Inhibitor)
      • AB-161 (Oral HBV RNA Destabilizers)
    • Coronavirus
  • Partners
    • Partnering & Licensing
    • Collaborations & Partners
  • Investors
    • Investor Center
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Investor FAQ
    • Contact Us

Investor Relations

  • Investor Center
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Press Releases
  • Events & Presentations
  • Investor FAQ
  • Contact Us

SEC Filing Details

Document Details

Form
DEF 14A
Filing Date
Apr 11, 2022
Document Date
May 25, 2022
Form Description
Official notification to shareholders of matters to be brought to a vote ("Proxy")
Filing Group
Proxy Filings
Company
Arbutus Biopharma Corporation
Issuer
ARBUTUS BIOPHARMA CORP

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

Shareholder Tools

  • Email Alerts Email Alerts
  • RSS News Feeds RSS News Feeds
  • Download Library Download Library

© 2022 Arbutus Biopharma

Legal Terms